Hyunjin Yang
Director of Business Development Ubix Therapeutics
Dr. Hyunjin Yang is the Director of Business Development at Ubix Therapeutics, leading global partnering and licensing strategies. With 20 years of combined experience in industry and academia, she has a strong track record in partnership development, IPO preparation, and life science research. Prior to joining Ubix, Dr. Yang served as Executive Director at Syntekabio, where she led strategic partnerships and alliances in AI-based drug discovery and contributed to the company’s successful KOSDAQ IPO. She earned her PhD in Molecular, Cellular, Developmental Biology and Genetics from the University of Minnesota and completed postdoctoral research at the National Institutes of Health (NIH) in the U.S.
Seminars
- Understanding Korean venture capital expectations to tailor fundraising strategies, attract competitive capital and enable sustainable biotech scaling
- Identifying how recent deals highlight investor priorities for emerging modalities including novel ligases, non-oncology-targeted degraders, and DACs to guide platform positioning and increase funding success
- Examining how early-stage proof-of-concept studies validate technology, strengthen investor confidence, and accelerate pharma partnership commitments
- Discussing how to structure successful biotech–pharma–academia collaborations in South Korea to balance expectations and maximize the translational speed of your TPD candidate
- Exploring how UBX-303-1 is a first-in-class, oral BTK/HCK/LYN degrader in Phase 1a for B-cell malignancies, demonstrating complete tumor regression in preclinical models and early signs of tumor response in the clinic
- Discussing how UBX-303-1 addresses key unmet medical needs by overcoming BTK inhibitor resistance in CLL and has the potential to introduce an oral treatment option for DLBCL patients
- Outlining how Ubix is advancing beyond CRBN-based degraders, expanding into Degrader-Antibody Conjugates (DACs) and novel E3 ligase binders
